Drug intelligence / Profile preview

Vanoxy

Development stage: Unknown
Lead developer: AstraZeneca

Overview

Vanoxy is a pharmaceutical drug for which a New Drug Application (NDA) was acquired by ANI Pharmaceuticals from AstraZeneca. This acquisition was part of AstraZeneca's divestment of mature, non-core assets, allowing them to focus on their innovative pipeline. ANI Pharmaceuticals aimed to expand its branded specialty pharmaceutical portfolio and leverage its manufacturing expertise to relaunch products like Vanoxy.

Brand names: Vanoxy

Beyond the preview

Go deeper on Vanoxy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vanoxy.

Explore the full profile